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Frailty has a stronger association with
inflammation than age in older veterans
P. Van Epps1,2*, D. Oswald2, P. A. Higgins1,4, T. R. Hornick1,3, H. Aung1,2, R. E. Banks1, B. M. Wilson1, C. Burant1,4,
S. Gravenstein3 and D. H. Canaday1,2
Abstract
Background: Upregulation of pro-inflammatory cytokines has not only been associated with increased morbidity
and mortality in older adults but also has been linked to frailty. In the current study we aimed to compare the
relative relationship of age and frailty on inflammation and thrombosis in older veterans.
Results: We analyzed 117 subjects (age range 62–95 years; median 81) divided into 3 cohorts: non-frail, pre-frail
and frail based on the Fried phenotype of frailty. Serum inflammatory markers were determined using commercially
available ELISA kits. Frail and pre-frail (PF) subjects had higher levels than non-frail (NF) subjects of IL-6 (NF vs. PF:
p = 0.002; NF vs. F: p < 0.001), TNFR1 (NF vs. F: p = 0.012), TNFRII (NF vs. F: 0.002; NF vs. PF: p = 0.005) and
inflammatory index: = 0.333*log(IL-6) + 0.666*log(sTNFR1) (NF vs. F: p = 0.009; NF vs. PF: p < 0.001). Frailty status
explained a greater percent of variability in markers of inflammation than age: IL-6 (12 % vs. 0.3 %), TNFR1
(5 % vs. 4 %), TNFR2 (11 % vs. 6 %), inflammatory index (16 % vs. 8 %). Aging was significantly associated with
higher fibrinogen (p = 0.04) and D-dimer levels (p = 0.01) but only among NF subjects.
Conclusion: In conclusion, these data suggest that among older veterans, frailty status has a stronger association
with inflammation and the inflammatory index than age does. Larger studies, in more diverse populations are
needed to confirm these findings.
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Background
The paradoxical phenomena of decline in immune func-
tion or immunosenescence and increased inflammation
are well described in aging. Immune dysregulation in
older adults results in imbalance between pro and anti-
inflammatory cytokines and consequently a low-grade
chronic inflammatory state [1, 2]. Upregulation of cyto-
kines such as interleukin-1 (IL-1), interleukin-6 (IL-6)
and tumor necrosis factor-α (TNF-α) that contribute to
systemic inflammation have been independently associ-
ated with increased morbidity and mortality in older
adults [3, 4]. It is now also well accepted that aging is as-
sociated with markers of activated coagulation, contrib-
uting to an overall pro-inflammatory state [5–7]. The
term “inflammaging” refers to this inflammatory state
and its association with age-associated diseases [8].
Besides the increased risk of morbidity, chronic in-
flammation has also been linked to functional decline in
older adults and has been theorized as a potential ex-
planation for the biologic basis of frailty [9, 10]. In this
study, frailty is defined according to Linda Fried’s pheno-
type as a biologic syndrome of decreased reserve and de-
creased resistance to stressors that is a strong marker
for poor health outcomes including falls, disability and
death [11]. There is growing link between frailty and in-
flammation. Elevated serum levels of IL6, TNF-α, and C-
reactive protein (CRP) have been linked with poor func-
tion and mobility status [9, 12]. Elevated levels of IL-6
have been associated with slower gait velocity and are
predictive of gait speed decline in community-dwelling
older adults [13]. Higher plasma IL-6 levels have also
been seen in older adults with performance deficits in
activities of daily living (ADLs) than those without any
functional deficits [14]. Similarly, markers of coagulation
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and endothelial dysfunction have been linked to frailty
and associated with poorer outcomes. D-dimer and
other markers of activated coagulation have been associ-
ated with limitation in a wide variety of functional do-
mains, including independent activities of daily living
[15, 16]. Frail and pre-frail subjects from the Cardiovas-
cular Health Study had significantly higher levels of fi-
brinogen, factor VIII, and D-dimer compared with the
non-frail group [17]. Frail adults are also at increased
risk of venous thromboembolism when compared with
non-frail persons of the same age [18]. Despite the
mounting evidence for role of inflammation and coagu-
lation in aging and frailty, measurements of inflamma-
tory markers have not yet been incorporated into
standard clinical practice, partly because a “gold stand-
ard” to reliably predict incident adverse outcomes in
older adults is needed. More recently, inflammatory
index, an additive index of serum IL-6 and soluble TNF-
α receptor −1 (TNFR1) has been shown not only to best
capture age-associated chronic inflammation but also
predict mortality in older adults [19]. There are limited
data regarding the inflammatory index in the context of
frailty. For that matter, data on the relative association of
age and frailty on inflammation and coagulation in older
adults is also lacking. In the present study, we examined
how age and frailty are related to an expanded set of in-
flammatory and coagulation markers.
Methods
Study subjects
We enrolled 117 veteran subjects, 60 years of age or
older (age range 62–95 years; median 81), receiving care
at the Louis Stokes Cleveland Veteran Affairs Medical
Center (LSCVAMC) outpatient clinics for this study. We
also enrolled 25 subjects, which included veteran and
non-veteran subjects, younger than 60 (age range 22–54,
median 39). Subjects receiving immunosuppressive
medications or with immunosuppressive conditions in-
cluding HIV, cancer undergoing chemotherapy, severe
anemia were excluded from the study. Each subject
underwent a blood draw for the measurements of in-
flammatory and coagulation markers. Informed consent
was obtained from all participants. Human experimenta-
tion guidelines of the Department of Health and Human
Services were followed in the conduct of this study.
The study was reviewed and approved by Institutional
Review Boards at the LSCVAMC and Case Western
Reserve University.
Frailty measurement
The Fried’s frailty assessment tool, a widely accepted and
validated instrument of frailty measurement in older
adults, was utilized for functional assessments [11].
Study staff administered the five components of Fried
frailty assessment tool: weakness as assessed by grip
strength (measured by Jamar dynamometer average of 3
trials with dominant hand), walking speed (15 feet,
straight line, one way), unintended weight loss > = 10
pounds in the past year, self-reported exhaustion (two
Likert-type questions from CES-D Depression Scale
[20]), and physical activity based on the Minnesota Leis-
ure Time activity questionnaire [21]. Grip strength was
stratified by sex and body mass index, walking speed
was stratified by sex and height and physical activity
score was stratified by sex as suggested by Fried and
colleagues. Subjects were assigned to the non-frail (NF)
category if for 0 criteria met, pre-frail (PF) for 1–2
criteria and frail (F) for 3 or more criteria met on the
Fried frailty instrument.
Biomarker measurements
Serum and soluble inflammatory and coagulation markers
were obtained using commercially available kits. Assays
were performed according to the manufacture’s protocols.
The following markers were measured in blood: pro-
inflammatory cytokines serum IL-6 (Human IL-6 Qunati-
kine HS Elisa Kit), serum IL-18 (Human IL-18/IL-1 F4
ELISA), soluble TNF-α receptor-1 (TNFR1) (Human
sTNF RI/TNFRSF1A Quantikine ELISA Kit), and soluble
TNF-α receptor-2 (TNFR2) (Human sTNF RII/
TNFRSF1B Quantikine ELISA Kit), Interferon gamma-
induced protein-10 (IP-10)(Human CXCL10/IP-10 Quan-
tikine ELISA Kit), soluble CD14 (Human CD14 Quanti-
kine ELISA Kit) (all R&D System, Minneapolis, MN,
USA) and pro-inflammatory protein C-reactive protein
(CRP) (EIA kit, Cayman Chemical Company, Ann Arbor,
MI, USA), Serum Amyloid A (SAA) (ELISA, Assaypro, St.
Charles, MO, USA) and were also measured. Inflamma-
tory index is a calculated parameter: 0.333*log (IL-6) +
0.666*log (sTNFR1). The following markers of thrombosis
and coagulation were also measured: Plasminogen activa-
tor inhibitor-1 (PAI-1) (AssayMax Human PAI-1 ELISA
kit, Assaypro, St. Charles, MO, USA), D-dimer (ELISA
ZYMUTEST DDimer, ANIARA, West Chester, OH, USA)
and Fibrinogen (immunoperoxidase assay, GenWay, San
Diego, CA, USA).
Statistical analysis
Analysis was completed in SPSS; Graphpad Prism 6.0
and R 3.2.2 using the ggplot2 packages were used to
graphically represent the data. ANOVA was used to
compare means of various biomarkers between frailty
groups. In cases where the frailty F statistic suggested a
significant overall affect, post hoc pairwise comparisons
were performed with p value adjustment with Bonferroni
or Tamhane, as determined by homogeneity of variance.
Associations between age and each biomarker measured
were examined using Spearman rank correlations. Log
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transformed values were used to represent correlations
with frailty groups. The Spearman Rank correlation is
robust to transformations and outliers. These correla-
tions were also examined within groups of frailty. The
explained variability in biomarkers, as measured by R-
squared values, obtained from Pearson correlations for
age and ANOVA for frailty group, was compared be-
tween age and frailty. The R-squared statistic measures
the percent of variability in an outcome explained by
one or more covariates. For a single continuous covari-
ate, it can be calculated as the square of the Pearson cor-
relation coefficient; for a single categorical variable, it
can be calculated as the regression sum of squares due
divided by the total sum of squares as summarized in
typical ANOVA results. Thus, comparing the squared
Pearson correlation coefficient to the ANOVA-based R-
squared allows the percent of variability in an outcome
explained by a categorical variable and a continuous
variable to be identically measured [22]. For patients
with available outpatient data from the two years prior
to enrollment, we also obtained outpatient diagnosis
codes from the electronic database and calculated the
Charlson comorbidity index using a validated list of
diagnosis codes [23]. The index was calculated, without
the addition of points for age, for 103 subjects (mean =
2.75, range = 0 to 8). We performed regression analyses
comparing the explained variability using comorbidity
and age vs. comorbidity and frailty.
Results
The one hundred and seventeen subjects over age 60
were divided into 3 cohorts based on the Fried frailty
measurement categories: non-frail (N = 23), pre-frail (N
= 50) and frail (N = 44). The median age in NF group
(68 years, range 62–90) was significantly lower than the
PF (80 years; 62–92) and frail (82 years; 62–92) groups
(p < 0.005 for both). As expected for an older veteran
population, majority of the subjects were male (96 %).
African Americans accounted for over half (54 %) of the
study subjects.
Markers of inflammation and the inflammatory index
among frailty groups
We compared all the markers of inflammation tested
among frailty groups. Frail and pre-frail subjects had
higher levels of markers incorporated into the Inflamma-
tory Index as well as a higher calculated Inflammatory
Index levels (Fig. 1). Mean IL-6 levels among frail sub-
jects were nearly three times those found in NF subjects
(1.88 pg/mL vs. 5.09 pg/mL; p < 0.001) and nearly twice
as high among PF subjects compared with NF subjects
(1.88 vs. 3.56; p = 0.002) than non-frail subjects. Similarly
TNFR1 levels were significantly higher among frail
subjects compared with NF subjects (1577 pg/mL vs.
2624 pg/mL; p = 0.012). Inflammatory index levels were
higher in both PF and frail groups compared with NF
group (NF vs. PF: p < 0.001; NF vs. F: p = 0.009). An add-
itional marker that was significantly elevated in both the
PF and frail groups was TNFRII (NF vs. F: 0.002; NF vs.
PF: p = 0.005; Fig. 2). The mean level of SAA was signifi-
cantly higher in frail group compared with NF group
(2.8 vs. 4.5; p = 0.035). Notably there were no differences
in markers of inflammation detected between PF and
frail subjects. We also did not find any significant differ-
ences among frailty groups between sCD14, IP10, CRP
and IL-18 levels (Fig. 2).
Frailty explains the variability in markers of inflammation
not age
When all the subjects were grouped together, using
Spearman Rank correlations, age was positively associ-
ated with TNFR1 (r = 0.22; p = 0.02), TNFR2 (r = 0.25;
p = 0.02) and the inflammatory index (r = 0.28, p =
0.008) but not IL-6 (r = 0.05; p = 0.5) (Fig. 3). No other
markers tested correlated with age in the cohort of pa-
tients over the age of 60 years (data not shown). When
correlations were tested within frailty status groups
however, there were no statistically significant associa-
tions between age and markers of inflammation (data
not shown). In order to determine whether frailty
status or age had a greater association with markers of
inflammation, the R2 values from ANOVA were com-
pared with R2 from spearman rank correlations. Frailty
status explained a greater percent of variability in
markers of inflammation than age: IL-6 (12 % vs.
0.3 %), TNFR1 (5 % vs. 4 %), TNFR2 (11 % vs. 6 %), in-
flammatory index (16 % vs. 8 %). We did not find any
significant interactions between age and frailty among
the markers of inflammation and coagulation tested.
For the subset of patients for which we had data avail-
able to calculate Charlson comorbidity index, we per-
formed regression analyses controlling for comorbidity.
After controlling for comorbidity, frailty explained more
of the variability compared with age in IL-6 levels (12 %
vs. 1.5 %), inflammatory index (18 % vs. 15 %), CRP (8 %
vs. 3 %), SAA (12 % vs. 1 %) sCD14 (8 % vs. 7 %). On the
other hand, after controlling for comorbidity, age was
slightly better at explaining variability in TNFR1 (18 % vs.
12 %) and TNFR2 (18 % vs. 16 %). We also examined rela-
tionship between CMV seropositivity and various inflam-
matory markers, however the vast majority of our subjects
were CMV+ (76 %) and we did not detect such a relation-
ship (data not shown).
Coagulation markers, frailty and age
Fibrinogen, PAI-1 and D-dimer levels were not signifi-
cantly different among frailty groups. Age was positively
associated with both fibrinogen (r = 0.21; p = 0.04) and
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D-dimer (r = 0.27; p = 0.01) (data not shown). However,
within frailty status groups, the only statistically significant
associations between age and coagulation markers were
seen in the NF group. Both D-dimer (r = 0.7, p = 0.001)
and Fibrinogen (r = 0.54; p = 0.02) were strongly positively
associated with age in this group (Fig. 4). Overall, age ex-
plained a greater percent of variability in fibrinogen (4.4 %
vs. 3.9 %) and D-dimer (7 % vs. 4 %) than frailty status.
After controlling for comorbidities using Charlson score
in a regression analysis, age explained more variability in
both D-dimer (11 % vs. 2 %) and fibrinogen (7 % vs. 6 %).
Discussion
In the present study we sought to determine the relative
effect of age compared with frailty on markers of inflam-
mation and coagulation in older adults. We observed
significant elevations in pro-inflammatory cytokines as
well as the inflammatory index among older adults who
were pre-frail or frail. While age was associated with
some of the markers studied, in particular the inflamma-
tory index, these associations were not present within
frailty groups. Additionally we also observed that the
variability in inflammatory markers was explained to a
much greater extent by frailty status than age. Coagula-
tion markers fibrinogen and D-dimer, on the other hand,
were not significantly different among frailty groups but
did correlate with age. These correlations persisted
among those with intact functional status. Age appeared
to explain the variability in coagulation markers more
than frailty.
Similar to prior studies we found elevations in IL-6,
SAA, TNFR1 and TNFR2 levels among those with func-
tional decline [4, 12, 14, 24, 25]. A measure validated in
older adults, the inflammatory index, which incorporates
two of these markers, has recently been shown to be in-
dependently associated with frailty among aging HIV-
infected and uninfected injection drug users [26]. We
also found the inflammatory index scores to be signifi-
cantly increased in frail and pre-frail older adults. Inter-
estingly, unlike a previous report where the greatest
differences between IL-6, TNF-α and CRP levels were
seen between the pre-frail and frail adults [27], we did
not see any significant differences between PF and frail
subjects. In our cohort, pre-frail inflammatory profile
Fig. 1 Inflammatory index and related markers among frailty groups. Comparisons are made using ANOVA between non-frail (circles), pre-frail
(squares) and frail (triangles) subjects as determined by the Fried’s Frailty assessment tool. In cases where the frailty F statistic suggested a significant
overall affect, post hoc pairwise comparisons were performed with p value adjustment with Bonferroni or Tamhane, as determined by homogeneity of
variance. Only significant p values are marked. Inflammatory index is a calculated parameter: 0.333*log (IL-6) + 0.666*log (sTNFR1)
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more closely resembled that of frail subjects than those
that were still functionally intact. While both the PF and
frail groups were significantly older than NF group, we
showed that in fact age did not explain variations in in-
flammatory markers as much as frailty status. This finding
may indicate that even before functional decline becomes
clinically apparent, the pro-inflammatory phenotype has
already been set in motion.
Age was associated with increased TNFR1 and TNFR2,
but unlike previously cited studies we did not find IL-6 or
CRP levels to be significantly associated with age in this co-
hort over 60 years of age. The data presented in this study
focused on those over the age of 60. When subjects of all
ages were included in the analysis, IL-6 did correlate with
age. Aging was associated with increasing inflammatory
index score in our study, as has previously been shown
[19]. However, age was not associated with the inflamma-
tory index, or any other markers, when frailty groups were
examined separately. This finding was confirmed by com-
paring the percentage of variability in markers explained
Fig. 2 Markers of inflammation among frailty groups. Comparisons are made using ANOVA between non-frail (circles), pre-frail (squares) and frail
(triangles) subjects as determined by the Fried’s Frailty assessment tool. In cases where the frailty F statistic suggested a significant overall affect,
post hoc pairwise comparisons were performed with p value adjustment with Bonferroni or Tamhane, as determined by homogeneity of variance.
Only statistically significant p values are marked
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by age vs. frailty. Frailty status had consistently greater as-
sociation with inflammation than did age. Interestingly, this
trend seemed to persist for most inflammatory markers,
particularly IL-6, inflammatory index and CRP, even after
controlling for comorbid conditions. This suggests that
while chronic inflammation is a feature of aging looking
over the entire age span, the inflammatory milieu is closely
linked with frailty such that irrespective of chronologic age,
frailty phenotype maybe a stronger predictor of chronic in-
flammation. However, as with other cross-sectional studies
demonstrating association between frailty and inflamma-
tion, our study provides no insights into causality. It has
been hypothesized that chronic inflammation may be the
driving force behind functional decline and may form the
biologic basis of age-associated conditions including frailty
[28, 29]. Elevated levels of IL-6 have been linked to mul-
tiple age-associated conditions, such as atherosclerosis
[30], dementia [31] and frailty [32], however causality and
pathogenesis is yet to be proven. It is also plausible that in-
creased levels of inflammatory cytokines maybe a compen-
satory mechanism in frailty and other age-associated
conditions. Inflammatory response maybe triggered by
chronic viral infections such as cytomegalovirus or other
herpes viruses [33]. We were unable to link CMV chronic
infection to inflammation due to very low numbers of sero-
negative subjects in our study. It is also possible that
markers of inflammation are simply a byproduct of another
causal mechanism of frailty such as excessive oxidative
stress. Frailty in older adults has been associated with
superoxide anion overproduction by nicotinamide adenine
dinucleotide phosphate-oxidase (NADPH) oxidase and
low-grade chronic inflammation [2]. Biomarkers of oxida-
tive stress have also been associated with frailty in the Fra-
mingham Offspring Study, suggesting oxidative stress as
the underlying mechanism contributing to frailty [34].
Whether targeted interventions at preventing functional
decline may result in an improved pro and anti-
inflammatory balance, regardless of age of the patient re-
mains to be established.
We also tested the associations between frailty and age
among markers of coagulation. In the present cohort
there were no differences between D-dimer and fibrino-
gen levels among frailty groups. Prior studies have linked
D-dimer and other markers of activated coagulation with
limitation in functional abilities [4, 35]. It has been
proposed that aging represents a pro-thrombotic state
and that some of the markers of coagulation and throm-
bosis begin to rise early during the process of aging,
Fig. 3 Spearman Rank correlations between age and markers of inflammation. The three frailty groups are combined for these comparisons
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suggesting a potential usefulness as markers for frailty
[3]. We did find aging to be not only associated with
both these coagulation markers but also more strongly
associated with a pro-thrombotic state than frailty status.
This association was present even after controlling for
comorbid conditions. Surprisingly, when age was exam-
ined within frailty groups, the association remained very
strong but only among non-frail subjects. This suggests
that while aging results in a pro-thrombotic state, its ef-
fect maybe less pronounced in those who already have
evidence of functional decline.
This study not only provides further evidence of
association between frailty and inflammation but also
demonstrates that chronological age maybe less
important than functional ability when it comes to
chronic inflammation among older adults. Further
studies are not only needed to establish the nature of
this association but also to investigate the effects of in-
terventions to prevent functional decline or modulate
the inflammatory cytokines in an effort to prevent age-
associated conditions.
Conclusion
In conclusion, among older adults, these data suggest
that frailty may be more strongly related to inflamma-
tion and the inflammatory index than age. Coagulation
factors, on the other hand appear to have a stronger as-
sociation with chronological age than frailty. These find-
ings warrant further investigation in larger, more diverse
populations.
Fig. 4 Spearman Rank correlations between age and markers of coagulation within frailty groups. Corresponding r and p values are listed for
each frailty group non-frail (star with dashed line), pre-frail (square with dotted line), frail (open circle with continuous line)
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